Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

While genetic screening is not a magic bullet, it has the potential to change the landscape of childhood cancer care in India ...

This metabolite disrupts normal cellular function and promotes tumor growth. Vorasidenib, a novel IDH inhibitor, works by deactivating the mutated IDH1/2 enzymes, halting the production of ...

“We were surprised to discover that KMT could work synergistically with the IDH1 mutation to simultaneously target ... using KMT and the a pan-glutaminase inhibitor—known as 6-diazo-5-oxo-L-norleucine ...

The Phase 3 INDIGO Trial was presented in the 2023 ASCO Presidential Plenary session. Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring monitoring and follow-up.